4-phenylbutyric acid has been researched along with Bile Duct Obstruction, Intrahepatic in 13 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Discontinuation of rifampin therapy, which had been used to treat pruritus, resulted in reversible severe acute liver injury that was potentially the result of phenylacetate toxicity." | 3.83 | Possible Phenylacetate Hepatotoxicity During 4-Phenylbutyrate Therapy of Byler Disease. ( Morris, A; Shneider, BL; Vockley, J, 2016) |
| " Therapy with 4PB had no beneficial effect for 1 month at 200 mg/kg/day and the next month at 350 mg/kg/day but partially restored BSEP expression at the canalicular membrane and significantly improved liver tests and pruritus at a dosage of 500 mg/kg/day." | 1.40 | Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. ( Hayashi, H; Igarashi, K; Inoue, T; Inui, A; Kage, M; Kusuhara, H; Nagai, T; Nagasaka, H; Naoi, S; Sugiyama, Y; Takikawa, H; Tanikawa, K, 2014) |
| "The therapeutic potency of 4PB in these patients was tested by oral administration of this drug with gradually increasing dosage (200, 350, and 500 mg/kg/day) for 6 months." | 1.40 | Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1. ( Bessho, K; Hanada, K; Hasegawa, Y; Hayashi, H; Igarashi, K; Kimura, T; Kondou, H; Konishi, A; Kusuhara, H; Miyoshi, Y; Nagasaka, H; Nakao, K; Naoi, S; Ozono, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Misawa, T | 1 |
| Hayashi, H | 6 |
| Sugiyama, Y | 4 |
| Hashimoto, Y | 1 |
| Nakano, S | 1 |
| Osaka, S | 1 |
| Sabu, Y | 1 |
| Minowa, K | 1 |
| Hirai, S | 1 |
| Kondou, H | 2 |
| Kimura, T | 2 |
| Azuma, Y | 1 |
| Watanabe, S | 1 |
| Inui, A | 2 |
| Bessho, K | 2 |
| Nakamura, H | 1 |
| Kusano, H | 1 |
| Nakazawa, A | 1 |
| Tanikawa, K | 2 |
| Kage, M | 2 |
| Shimizu, T | 1 |
| Kusuhara, H | 3 |
| Zen, Y | 1 |
| Suzuki, M | 1 |
| Amzal, R | 1 |
| Thébaut, A | 1 |
| Lapalus, M | 1 |
| Almes, M | 1 |
| Grosse, B | 3 |
| Mareux, E | 1 |
| Collado-Hilly, M | 1 |
| Davit-Spraul, A | 3 |
| Bidou, L | 1 |
| Namy, O | 1 |
| Jacquemin, E | 3 |
| Gonzales, E | 3 |
| Malatack, JJ | 1 |
| Doyle, D | 1 |
| Naoi, S | 2 |
| Inoue, T | 1 |
| Igarashi, K | 2 |
| Nagasaka, H | 2 |
| Takikawa, H | 1 |
| Nagai, T | 1 |
| Hasegawa, Y | 1 |
| Hanada, K | 1 |
| Nakao, K | 1 |
| Konishi, A | 1 |
| Miyoshi, Y | 1 |
| Ozono, K | 1 |
| Schuller, B | 1 |
| Conti, F | 1 |
| Guettier, C | 1 |
| Cassio, D | 2 |
| Shneider, BL | 1 |
| Morris, A | 1 |
| Vockley, J | 1 |
| van der Woerd, WL | 1 |
| Wichers, CG | 1 |
| Vestergaard, AL | 1 |
| Andersen, JP | 1 |
| Paulusma, CC | 1 |
| Houwen, RH | 1 |
| van de Graaf, SF | 1 |
| Fabre, M | 1 |
| Lam, P | 1 |
| Pearson, CL | 1 |
| Soroka, CJ | 1 |
| Xu, S | 1 |
| Mennone, A | 1 |
| Boyer, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 4-phenylbutyric acid and Bile Duct Obstruction, Intrahepatic
| Article | Year |
|---|---|
A Drug Regimen for Progressive Familial Cholestasis Type 2.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; Benzothiepins; Biological Transport; Carba | 2018 |
12 other studies available for 4-phenylbutyric acid and Bile Duct Obstruction, Intrahepatic
| Article | Year |
|---|---|
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
Topics: Amino Acid Substitution; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Bind | 2012 |
Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; Child; Child, Presc | 2019 |
Pharmacological Premature Termination Codon Readthrough of ABCB11 in Bile Salt Export Pump Deficiency: An In Vitro Study.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Cholestasis, Intrahepatic; Codon, | 2021 |
Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Cholest | 2014 |
Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Cholestasis, Intrahepatic; Disease Progre | 2014 |
Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2015 |
Possible Phenylacetate Hepatotoxicity During 4-Phenylbutyrate Therapy of Byler Disease.
Topics: Antineoplastic Agents; Bilirubin; Chemical and Drug Induced Liver Injury; Child, Preschool; Cholesta | 2016 |
Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis.
Topics: Adenosine Triphosphatases; Cell Line, Tumor; Cell Polarity; Cholestasis, Intrahepatic; Cystic Fibros | 2016 |
Short-chain ubiquitination is associated with the degradation rate of a cell-surface-resident bile salt export pump (BSEP/ABCB11).
Topics: Adenoviridae; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member | 2009 |
Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassett | 2012 |
4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Bindin | 2007 |
Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2007 |